Four Major Developments in Multiple Myeloma: ASH 2018
Frontline Monoclonal Antibody Therapy for Multiple Myeloma The first is the move toward monoclonal antibody therapy in frontline multiple myeloma. Earlier this year, the US Food and Drug Administration (FDA) approved daratumumab in combination with bortezomib, melphalan, and prednisone in patients who were ineligible for an autologous stem cell transplant, based on a clinical trial that demonstrated… Read More »Four Major Developments in Multiple Myeloma: ASH 2018